SGPP2通过SIRT1/AMPK通路减弱ESR来改善慢性心力衰竭
Yang Kang1, Yang Wang2, Lili Wang1
1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, No. 199 Dongdazhi Street, Nangang District, Harbin 150001, China.
Current issues in molecular biology
|January 30, 2026
概括
氨酸-1-酸酶2 (SGPP2) 通过通过SIRT1/AMPK通路减少内分泌网膜应激 (ERS) 来保护心力衰竭. 这一发现为缺血性心肌病引起的心力衰竭 (IHF) 提供了一个新的治疗点.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 缺血性心肌病引起的心力衰竭 (IHF) 是一个重要的健康问题.
- 细胞内膜网膜应激 (ERS) 在IHF的发病过程中起着至关重要的作用.
- 在IHF和ERS背后的精确分子机制需要进一步阐明.
研究的目的:
- 通过SIRT1/AMPK通路调查基-1-酸酶2 (SGPP2) 在调节内分泌网膜应激 (ERS) 中的作用.
- 确定SGPP2是否可以改善缺血性心肌病引起的慢性心力衰竭 (IHF).
主要方法:
- 生物信息学分析以确定IHF和ERS中的关键基因和途径.
- 在生体内对诱导IHF的老鼠进行研究,以评估心脏功能,心肌损伤,纤维化和SGPP2表达.
- 使用新生小鼠心肌细胞 (NRCMs) 进行体外研究,这些新生小鼠心肌细胞 (NRCMs) 接受了氧气-葡萄糖剥夺 (OGD) 并用尼卡米辛或SIRT1抑制剂治疗.
- 西部涂抹 (WB) 和免疫组织化学评估蛋白质表达和信号通路活性.
主要成果:
- 包括SGPP2在内的六个关键基因被确定;SGPP2在IHF下调并与AMPK信号通路相关.
- 在体内,IHF大鼠表现出心脏功能受损,心肌损伤,纤维化,ERS,以及SGPP2和SIRT1/AMPK活性降低.
- 在体外,SGPP2过度表达通过抑制ERS和激活SIRT1/AMPK通路,保护心肌细胞免受OGD诱导的损伤.
结论:
- SGPP2通过SIRT1/AMPK通路抑制ESR,在IHF中起着保护作用.
- SGPP2代表了管理IHF的潜在治疗目标.
- 准SGPP2可能提供一种新的策略,以减轻心力衰竭中ERS介导的心脏功能障碍.
更多相关视频
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
3.4K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
相关概念视频
01:29Heart Failure II: Pathophysiology
907
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
877
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
01:22Heart Failure VI: Adjunct Therapies
332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
01:22Heart Failure Drugs: Diuretics
963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
01:30Heart Failure V: Medical Management
308
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308